BioCopy developed an innovative, patented technique to copy biomolecules analogous to a photocopier.
BioCopy has raised $11.3M in total funding. The most recent round was Series A. The last funding was announced in March 2026.
BioCopy's investors include EISMEA, Haute Capital Partners.
BioCopy is headquartered in Freiburg, Germany.
BioCopy developed an innovative, patented technique to copy biomolecules analogous to a photocopier.
BioCopy is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"BioCopy — Funding & Investors." VCBacked, March 13, 2026, https://www.vcbacked.co/company/biocopy. Accessed September 9, 2026.
VCBacked. (2026). BioCopy — Funding & Investors. Retrieved September 9, 2026, from https://www.vcbacked.co/company/biocopy
{{cite web |title=BioCopy — Funding & Investors |url=https://www.vcbacked.co/company/biocopy |website=VCBacked |access-date=September 9, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated